Tactile Systems Posts 31c Q3 EPS as Lymphedema Sales Jump 13%
TCMD sits 54% above its 52-week low of $14.84.
Summary
Tactile Medical reported Q3 2026 EPS of 31 cents alongside revenue of $91.9M, up 7% year over year, and net income of $7.2M. Lymphedema sales grew 13% and offset a 25% drop in airway clearance, so the growth is coming from the core franchise while the legacy airway line keeps shrinking. The top line builds on Q2's $85.7M (up 9%, a slight beat) and Q1's 23% revenue jump to $75.3M, though the growth rate has clearly decelerated through the year. The company sees FY revenue of $360M-$366M and raised its 2026 adjusted EBITDA guidance. The 8-K with the full results hit the wire minutes before this headline; the EPS print is the number traders will key on against consensus.
At the time of this announcement, TCMD was trading at $22.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $518.1M. The 52-week trading range was $14.84 to $37.77. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.